Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$32.01 USD

32.01
1,959,949

+0.44 (1.39%)

Updated May 31, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sanofi's (SNY) Diabetes Drug Toujeo Lowers Hypoglycemia Risk

by Zacks Equity Research

A real-world observational study showed that when type 2 diabetes patients on basal insulin switched to Toujeo, it led to a significant reduction in risk of hypoglycemia without compromising blood sugar control

    Bristol-Myers (BMY), Incyte to Advance Clinical Program

    by Zacks Equity Research

    Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.

      AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval

      by Zacks Equity Research

      AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received full approval from the FDA.

        Pfizer Gets Regular Approval for Breast Cancer Drug Ibrance

        by Zacks Equity Research

        Pfizer, Inc. (PFE) announced that its supplemental new drug application (sNDA) to convert accelerated approval for Ibrance to regular approval has been approved by the FDA.

          Arpita Dutt headshot

          4 FDA Decisions to Watch Out for in Apr 2017

          by Arpita Dutt

          Companies like BioMarin (BMRN), Roche and Takeda among others have regulatory decisions scheduled for this month.

            Mylan Receives CRL for Generic Advair Diskus From the FDA

            by Zacks Equity Research

            Mylan N.V. (MYL) recently suffered a huge setback when it received a complete response letter from the FDA regarding its ANDA for the generic version of asthma drug Advair Diskus.

              AbbVie's (ABBV) Humira Drug Label Update Approved by FDA

              by Zacks Equity Research

              AbbVie Inc.'s (ABBV) announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie???s multi-utility TNF blocker drug, Humira

                Arpita Dutt headshot

                Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?

                by Arpita Dutt

                Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.

                  Roche's Rituxan Gets FDA Advisory Committee's Recommendation

                  by Zacks Equity Research

                  Roche Holding AG's (RHHBY) member, Genentech announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of subcutaneous Rituxan /hyaluronidase for the treatment of patients with certain blood cancers.

                    Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis

                    by Zacks Equity Research

                    Roche Holdings AG (RHHBY) announced that the FDA has approved Ocrevus (ocrelizumab) as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis.

                      AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA

                      by Zacks Equity Research

                      AstraZeneca plc (AZN) announced that the FDA has accepted the new drug application (NDA) for Lynparza (300mg twice daily) for the maintenance treatment of patients suffering from platinum sensitive relapsed ovarian cancer with the germline BRCA mutation

                        AstraZeneca's Lung Cancer Drug Tagrisso Approved in China

                        by Zacks Equity Research

                        AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received approval in China.

                          Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA

                          by Zacks Equity Research

                          Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.

                            Amgen's (AMGN) Humira Biosimilar Receives Approval in EU

                            by Zacks Equity Research

                            Amgen, Inc. (AMGN) announced that its biosimilar version of AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira has been approved by the European Commission (EC).

                              Should Value Investors Pick Roche Holding (RHHBY)?

                              by Zacks Equity Research

                              Roche Holding (RHHBY) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

                                Inovio (INO) Q4 Loss Wider than Expected; Shares Decline

                                by Zacks Equity Research

                                Inovio Pharmaceuticals, Inc. (INO) reported a loss of 36 cents for the fourth quarter of 2016.

                                  Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat

                                  by Zacks Equity Research

                                  Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.

                                    Arpita Dutt headshot

                                    How Incyte Stock Became a Bull Market Star for Biotech Investors

                                    by Arpita Dutt

                                    Incyte (INCY) tops the list of stocks that enjoyed a stupendous run in the last 8 years.

                                      Immune Design (IMDZ) Q4 Loss In Line; Sales Beat Estimates

                                      by Zacks Equity Research

                                      Immune Design Corp.(IMDZ) reported fourth-quarter 2016 loss of 57 cents per share, in line with Zacks Consensus Estimate but narrower than the year-ago loss of 60 cents.

                                        Can Epizyme (EPZM) Spring a Surprise This Earnings Season?

                                        by Zacks Equity Research

                                        Epizyme, Inc. (EPZM) is scheduled to report fourth-quarter 2016 results on Mar 9, before the opening bell.

                                          The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi

                                          by Zacks Equity Research

                                          The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi

                                            Arpita Dutt headshot

                                            5 FDA Decisions to Watch Out for in Mar 2017

                                            by Arpita Dutt

                                            Companies like Merck (MRK) are awaiting key FDA decisions this month.

                                              What's in Store for Immune Design (IMDZ) in Q4 Earnings?

                                              by Zacks Equity Research

                                              Immune Design Corp (IMDZ) is scheduled to report fourth-quarter 2016 results after the market closes on Mar 7.

                                                Arpita Dutt headshot

                                                Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug

                                                by Arpita Dutt

                                                Quite a few companies including AstraZeneca (AZN) provided pipeline/regulatory updates this week.

                                                  Mylan (MYL) Beats on Q4 Earnings, Stock Up on Strong View

                                                  by Zacks Equity Research

                                                  Shares of Mylan N.V.'s (MYL) were up 7.2% after the company beat expectations in the fourth-quarter 2016 and provided a strong outlook for 2017 amid challenging conditions.